About US
We have developed a new omics platform that accurately detects cell states by profiling terminal surface glycans. By reading this overlooked biological layer, we extract real-time cell state information non-invasively. This unlocks new applications across cell biology, drug development, and diagnostics.
Cell state defines biology: From healthy to diseased, ageing to apoptotic, cycling to differentiated, medicine and drug development depend on understanding these transitions.
Today, cell states are measured by breaking cells open and analysing internal components. These invasive methods are slow, destructive, and poorly suited for dynamic or scalable applications. Additionally, they capture only a partial snapshot, a biochemical shadow, of what the cell was before disruption.
By contrast, our platform reads cell state in real time from the intact cell surface.
This enables dynamic, non-destructive analysis of cellular health and disease.
Our patented Cell State Fingerprint (CSF) platform profiles terminal surface glycan motifs and integrates them with selected biomarkers through our proprietary cell-state analysis software.
Because these markers are ubiquitous, the platform applies across:
All species All cell types All cell states
Therefore, CSF provides a universal, non-invasive framework for measuring cellular health and disease.
We are building a scalable ecosystem of research tools and diagnostic applications based on this surface readout layer.
Intellectual Property
We have built a protected platform supported by a structured and expanding intellectual property portfolio.
Our core technology is secured by four patents covering:
- – The biological basis of surface sugar state detection,
- – The analytical framework for cell-state classification,
- – Software-driven interpretation of multi-marker surface data,
- – Platform applications across research and diagnostics.
This IP protects both the biological insight and the computational architecture that underpin CSF.
The platform is designed to be modular and expandable.
The originating IP was developed in collaboration with The University of Aberdeen and Loughborough University. Both institutions are shareholders and strategic partners in the company.
Product Portfolio
We are launching our first commercial products focused on: Programmed Cell Death, cellular ageing (senescence) and other core cell-state transitions in biology.
The CSF platform can be deployed in two ways:
Defined Mode – targeted kits for high-value, well-characterised cell-state applications (e.g. apoptosis, ageing, therapeutic response).
Exploratory Mode – open-format tools enabling researchers and biopharma teams to profile cell-state shifts in custom systems.
The technology is being developed across three scalable formats:
- – Research-use kits,
- – High-throughput drug discovery screening platforms,
- – Optimisation tools for cell therapy manufacturing (Stem Cell and CAR-T).
This creates multiple revenue pathways across research, pharma, and advanced therapeutics.
Our philosophy
Cell state is the central variable in biology and medicine.
We are building technologies that make it measurable, reproducible, and scalable.
By integrating biological insight with computational analysis, we aim to transform how cell biology is translated into therapeutics and diagnostics.
Our goal is simple: deliver tools that improve outcomes for researchers, companies, and ultimately patients.
The team
Dr Paul Burrows, CEO
Founder & Inventor. Paul holds a PhD in biochemistry/cell biology from Imperial College London, and an MBA from Imperial College London.
Dr Patrick Cao, CsO
Founder & Inventor. Patrick holds a degree in natural Sciences from Cambridge University and a PhD from Cambridge University
Dr Dimitris Tampakis, CTo
Founder & Inventor. Dimitris holds a degree from The Democritus University of Thrace, an MSc from Aberdeen University, and a PhD from Loughborough University.
LectomeBio is supported by board representation from its founding university partners and an expanding advisory group with expertise across clinical medicine, immunology, and translational biology.